---
title: AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
nct_id: NCT07009769
overall_status: COMPLETED
sponsor: Korea University Guro Hospital
study_type: OBSERVATIONAL
primary_condition: Lung Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07009769.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07009769"
ct_last_update_post_date: 2025-06-08
last_seen_at: "2026-05-12T07:05:33.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

**Official Title:** Retrospective Clinical Study for Developing an AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

**NCT ID:** [NCT07009769](https://clinicaltrials.gov/study/NCT07009769)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 865
- **Lead Sponsor:** Korea University Guro Hospital
- **Conditions:** Lung Cancer
- **Start Date:** 2024-10-16
- **Completion Date:** 2025-05-01
- **CT.gov Last Update:** 2025-06-08

## Brief Summary

The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria (Patients)

* Republic of Korea nationality
* Age ≥ 30 years
* Lung cancer based on radiologic and/or histopathologic examination
* No prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection

Exclusion Criteria (Patients)

* History of other cancers before blood collection
* Prior cancer treatment before blood collection
* Incomplete clinical data
* No consent for sample use

Inclusion Criteria (Healthy Controls):

* Republic of Korea nationality
* No history of any cancer
* Age ≥ 30 years

Exclusion Criteria (Healthy Controls):

* History of any malignancy
* Incomplete clinical information or no consent for sample use
```

## Primary Outcomes

- **Diagnostic accuracy of the AI-based classification model using SERS signals from plasma-derived exosomes** _(time frame: Retrospective, based on pre-collected samples through study completion, an average of 1 year)_ — To evaluate the diagnostic performance (sensitivity, specificity, and overall accuracy) of a machine learning model trained on SERS spectral data of plasma-derived exosomes in distinguishing lung cancer patients from healthy controls.

## Locations (1)

- Korea University Guro Hospital, Guro-gu, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.korea university guro hospital|guro-gu|seoul|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07009769.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07009769*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*